IL162822A - Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis - Google Patents
Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeisInfo
- Publication number
- IL162822A IL162822A IL162822A IL16282204A IL162822A IL 162822 A IL162822 A IL 162822A IL 162822 A IL162822 A IL 162822A IL 16282204 A IL16282204 A IL 16282204A IL 162822 A IL162822 A IL 162822A
- Authority
- IL
- Israel
- Prior art keywords
- pdeis
- medicaments
- agonists
- antagonists
- identifying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202282.0A GB0202282D0 (en) | 2002-01-31 | 2002-01-31 | Treatment of male sexual dysfunction |
| PCT/IB2003/000140 WO2003064402A1 (en) | 2002-01-31 | 2003-01-20 | Treatment of male sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162822A true IL162822A (en) | 2010-11-30 |
Family
ID=9930155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16282203A IL162822A0 (en) | 2002-01-31 | 2003-01-20 | Treatment of male sexual dysfunction |
| IL162822A IL162822A (en) | 2002-01-31 | 2004-07-01 | Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16282203A IL162822A0 (en) | 2002-01-31 | 2003-01-20 | Treatment of male sexual dysfunction |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1470115A1 (en) |
| JP (3) | JP2005525321A (en) |
| KR (2) | KR100829262B1 (en) |
| CN (1) | CN100500658C (en) |
| AU (1) | AU2003201471B2 (en) |
| BR (1) | BR0307337A (en) |
| CA (1) | CA2474590A1 (en) |
| GB (1) | GB0202282D0 (en) |
| HK (1) | HK1073109A1 (en) |
| IL (2) | IL162822A0 (en) |
| MX (1) | MXPA04007434A (en) |
| NZ (1) | NZ546408A (en) |
| PL (1) | PL371415A1 (en) |
| TW (1) | TW200302732A (en) |
| WO (1) | WO2003064402A1 (en) |
| ZA (1) | ZA200405208B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3646871A1 (en) * | 2018-10-30 | 2020-05-06 | SEROJAC PME Handels GmbH | Treatment and prevention of premature ejaculation (pe) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
| GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
| EP0679084A1 (en) * | 1992-12-23 | 1995-11-02 | Merck & Co. Inc. | Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists |
| US5693805A (en) * | 1993-03-12 | 1997-12-02 | Merck & Co., Inc. | Process to derivatives of piperizinylcamphorsulfonyl oxytocin antagonists |
| GB0007884D0 (en) | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
| US20020028799A1 (en) * | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
-
2002
- 2002-01-31 GB GBGB0202282.0A patent/GB0202282D0/en not_active Ceased
-
2003
- 2003-01-20 MX MXPA04007434A patent/MXPA04007434A/en active IP Right Grant
- 2003-01-20 WO PCT/IB2003/000140 patent/WO2003064402A1/en active Application Filing
- 2003-01-20 KR KR1020047011672A patent/KR100829262B1/en not_active IP Right Cessation
- 2003-01-20 NZ NZ546408A patent/NZ546408A/en not_active IP Right Cessation
- 2003-01-20 BR BR0307337-8A patent/BR0307337A/en not_active IP Right Cessation
- 2003-01-20 EP EP03700164A patent/EP1470115A1/en not_active Withdrawn
- 2003-01-20 AU AU2003201471A patent/AU2003201471B2/en not_active Expired
- 2003-01-20 IL IL16282203A patent/IL162822A0/en unknown
- 2003-01-20 CN CNB038030535A patent/CN100500658C/en not_active Expired - Lifetime
- 2003-01-20 CA CA002474590A patent/CA2474590A1/en not_active Abandoned
- 2003-01-20 KR KR1020077029747A patent/KR20080011232A/en not_active Application Discontinuation
- 2003-01-20 JP JP2003564025A patent/JP2005525321A/en not_active Ceased
- 2003-01-20 PL PL03371415A patent/PL371415A1/en not_active Application Discontinuation
- 2003-01-27 TW TW092101731A patent/TW200302732A/en unknown
-
2004
- 2004-06-30 ZA ZA2004/05208A patent/ZA200405208B/en unknown
- 2004-07-01 IL IL162822A patent/IL162822A/en active IP Right Grant
-
2005
- 2005-07-11 HK HK05105801.3A patent/HK1073109A1/en not_active IP Right Cessation
-
2010
- 2010-03-30 JP JP2010079241A patent/JP2010209075A/en not_active Withdrawn
-
2013
- 2013-02-28 JP JP2013038357A patent/JP2013151511A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200405208B (en) | 2005-08-31 |
| JP2010209075A (en) | 2010-09-24 |
| GB0202282D0 (en) | 2002-03-20 |
| NZ546408A (en) | 2007-10-26 |
| JP2005525321A (en) | 2005-08-25 |
| CN1625553A (en) | 2005-06-08 |
| CA2474590A1 (en) | 2003-08-07 |
| KR100829262B1 (en) | 2008-05-13 |
| IL162822A0 (en) | 2005-11-20 |
| BR0307337A (en) | 2004-12-07 |
| WO2003064402A1 (en) | 2003-08-07 |
| PL371415A1 (en) | 2005-06-13 |
| MXPA04007434A (en) | 2004-10-11 |
| KR20080011232A (en) | 2008-01-31 |
| CN100500658C (en) | 2009-06-17 |
| KR20040079958A (en) | 2004-09-16 |
| AU2003201471B2 (en) | 2009-03-26 |
| EP1470115A1 (en) | 2004-10-27 |
| TW200302732A (en) | 2003-08-16 |
| JP2013151511A (en) | 2013-08-08 |
| HK1073109A1 (en) | 2005-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL168056A0 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
| PL376373A1 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
| HUP0303081A3 (en) | Thrombin receptor antagonists, pharmaceutical compositions containing them and their use | |
| IL174647A (en) | Pyrazolopyridines and analogs thereof, pharmaceutical compositions comprising them and their use in the manufacture of medicaments | |
| EP1541585A4 (en) | Cxcr4 antagonist and use thereof | |
| PL1732917T3 (en) | Selected cgrp antagonists, methods for the production thereof and their use as medicaments | |
| HK1084394A1 (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use for preparing neurokinin antagonists | |
| HUP0401643A3 (en) | Substituted urea neuropeptide y y5 receptor antagonists, their use and pharmaceutical compositions containing them | |
| CL2008001920A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AN PDE 2 INHIBITOR, AN E2 SELECTIVE RECEIVER AGONIST AND A CARRIER; AND USE IN THE TREATMENT OF FRACTURE AND / OR OSEO DEFECT (DIV. SOL. 3179-04). | |
| HUP0600057A2 (en) | Glutaminyl based dpiv inhibitors, pharmaceutical compositions comprising thereof and their use | |
| NO20052739D0 (en) | CCR5 antagonists as drugs | |
| HUP0302969A3 (en) | Npyy5 antagonists, pharmaceutical compositions containing them and their use | |
| HK1072559A1 (en) | Methods and dosage forms for controled delivery ofpaliperidone | |
| WO2004082623A3 (en) | Substituted piperidine compounds | |
| HUP0400349A3 (en) | Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them | |
| HUP0200438A3 (en) | Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them | |
| IL163613A (en) | Partial or full agonists of a1 adenosine receptors and pharmaceutical compositions comprising the same | |
| EP1536813A4 (en) | Compositions and methods comprising protein activated receptor antagonists | |
| EP2301625A3 (en) | Compositions and methods for treating cognitive disorders | |
| HUP0300599A3 (en) | Il-8 receptor antagonists, pharmaceutical compositions containing them and their use | |
| IL161834A0 (en) | Pharmaceutical compositions and methods for administering ep2 receptor selective agonists | |
| IL198759A (en) | Use of gal3 receptor antagonists for the preparation of medicaments for treatment of depression and/or anxiety | |
| AU2003267088A8 (en) | Chemokine receptor antagonists as therapeutic agents | |
| IL179974A0 (en) | Substituted tetrahydroiso quinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drugs | |
| HUP0203976A3 (en) | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |